• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Von Willebrand Factor Activation Assays Predict Bleeding And Other Hemocompatibility-Related Adverse Events In Patients With CF-LVAD.
Bleeding and hemocompatibility-related adverse events (HRAEs - bleeding, neurological event, stroke, arterial thrombosis, pump thrombosis, and death) remain significant in LVAD patients; changes in coagulation homeostasis, mainly due to von Willebrand Factor (vWF) structural and functional changes induced by mechanical support have been considered a major player in these adverse events. However, the specific mechanisms and the clinical correlation between coagulation profile parameters and clinical outcomes are not yet completely clarified.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Bansi Vekaria, Eleonora Avenatti, Aayush Shah, Ju Kim, Rayan Yousefzai, Imad Hussain, Ashrith Guha, Arvind Bhimaraj, Janardhana Gorthi, Jian Chen, Edward A Graviss, Duc T Nguyen, Marcos De Oliveira, Lin-Chiang Philip Chou, Erik Suarez, Thomas E. MacGilliv Tags: 193 Source Type: research

Risk Of Pump Thrombosis With Once Daily Enoxaparin For Anticoagulation Bridging In Patients With Heartmate III
Most centers bridge patients with Left Ventricular Assist Device (LVAD) with heparin drip to avoid thromboembolic complications including stroke and pump thrombosis based on data from HeartMate II. Because of improved hemocompatibility of third generation HeartMateIII (HM3), particularly the decreased risk of in-pump thrombosis, outpatient treatment dose of low molecule weight heparin (LWMH) like Enoxaparin has been used to bridge to warfarin when the INR is subtherapeutic. Once daily dosing has been used in select patients with higher bleeding risk.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Modar Alom, Gurjaspreet Bhattal, Nitin Kabra, David Rawitscher, Amit Alam, Cesar Guerrero-Miranda, Sandra Carey, Timothy George, Aasim Afzal Tags: 180 Source Type: research

Hemodynamic Aberrancies in Left Ventricular Assist Device Associated Heart Failure Syndromes
The advent of the fully magnetically levitated HeartMate 3 LVAD has enabled a marked reduction in hemocompatibility-related adverse events, with a near-elimination of pump thrombosis, and a marked decrease in stroke in LVAD recipients.1,2 As a result, a survival benchmark for LVAD therapy has been established – prolongation of median survival more than 5-years, in patients with advanced heart failure with otherwise severely limited 1-year survival.3
Source: Journal of Cardiac Failure - September 25, 2022 Category: Cardiology Authors: Jacinthe Boulet, Aditi Nayak, Mandeep R. Mehra Tags: JCF Ignite! Source Type: research

Hemodynamic Aberrancies in Left Ventricular Assist Device –Associated Heart Failure Syndromes
The advent of the fully magnetically levitated HeartMate 3 left ventricular assist device (LVAD) has enabled a marked reduction in hemocompatibility-related adverse events, with a near-elimination of pump thrombosis, and a marked decrease in stroke in LVAD recipients.1,2 As a result, a survival benchmark for LVAD therapy has been established —prolongation of the median survival of more than 5 years in patients with advanced heart failure with otherwise severely limited 1-year survival.3
Source: Journal of Cardiac Failure - September 25, 2022 Category: Cardiology Authors: JACINTHE Boulet, ADITI Nayak, MANDEEP R. Mehra Tags: JCF Ignite! Source Type: research

Heart Failure With Sinus Rhythm: Does Anticoagulation Reduce Stroke at All?
Heart failure (HF) carries substantial risk of thromboembolism with or without concomitant atrial fibrillation (AF).1 –3 Patients with recent HF are almost twice likely to develop ischemic stroke compared with matched controls in a large cohort without AF (incidence of 2.23 per 100 person-years vs 1.17 per 100 person-years).2 The prothrombotic state in HF could be explained by the elements fulfilling Virchow tria d in HF population: decreased cardiac output, abnormal haemostasias and platelet function, and endothelial dysfunction.
Source: Journal of Cardiac Failure - August 1, 2021 Category: Cardiology Authors: Juqian Zhang, Eduard Shantsila, Gregory Y.H. Lip Tags: Editorial Source Type: research

Presence of intracardiac thrombus at the time of left ventricular assist device implantation is associated with increased risk of stroke and death
Left ventricular assist device
Source: Journal of Cardiac Failure - June 20, 2021 Category: Cardiology Authors: Claudio A. Bravo, Justin A. Fried, Joshua Z. Willey, Azka Javaid, Giulio M. Mondellini, Lorenzo Braghieri, Heidi Lumish, Veli K. Topkara, Yuji Kaku, Lucas Witer, Hiroo Takayama, Koji Takeda, Gabriel Sayer, Nir Uriel, Ryan T. Demmer, Yoshifumi Naka, Melana Source Type: research

Increased Aortic Stiffness is Associated with Higher Rates of Stroke, GI-bleeding and Pump Thrombosis in CF-LVAD Patients
In the general population, increased aortic stiffness is associated with an increased risk of cardiovascular events. Previous studies have demonstrated an increase in aortic stiffness in continuous-flow left ventricular assist device (CF-LVAD) patients. However, the association between aortic stiffness and common adverse events  is unknown.
Source: Journal of Cardiac Failure - February 23, 2021 Category: Cardiology Authors: Hannah Rosenblum, Alberto Pinsino, Amelia Zuver, Azka Javaid, Giulio Mondellini, Ruiping Ji, John R. Cockcroft, Melana Yuzefpolskaya, A. Reshad Garan, Sofia Shames, Veli K. Topkara, Hiroo Takayama, Koji Takeda, Yoshifumi Naka, Barry J. McDonnell, Joshua Z Tags: Brief Report Source Type: research

Increased Aortic Stiffness Is Associated With Higher Rates of Stroke, Gastrointestinal Bleeding and Pump Thrombosis in Patients With a Continuous Flow Left Ventricular Assist Device
In the general population, increased aortic stiffness is associated with an increased risk of cardiovascular events. Previous studies have demonstrated an increase in aortic stiffness in patients with a continuous flow left ventricular assist device (CF-LVAD). However, the association between aortic stiffness and common adverse events  is unknown.
Source: Journal of Cardiac Failure - February 23, 2021 Category: Cardiology Authors: Hannah Rosenblum, Alberto Pinsino, Amelia Zuver, Azka Javaid, Giulio Mondellini, Ruiping Ji, John R. Cockcroft, Melana Yuzefpolskaya, A. Reshad Garan, Sofia Shames, Veli K. Topkara, Hiroo Takayama, Koji Takeda, Yoshifumi Naka, Barry J. Mcdonnell, Joshua Z Tags: Brief Report Source Type: research

A Rare Case of Myocarditis, Intracardiac Thrombus And Embolic Stroke Caused By Mycoplasma Pneumoniae
We describe a rare case of mycoplasma pneumoniae myocarditis complicated by acute systolic heart failure, left ventricular thrombus and embolic stroke.
Source: Journal of Cardiac Failure - September 30, 2020 Category: Cardiology Authors: Raksha Kulkarni, Mansi Oberoi, Tony Oliver Tags: 176 Source Type: research

Role of Gallium-SPECT-CT in the Management of Patients with Ventricular Assist Device-Specific Percutaneous Driveline Infection
Implantable left ventricular assist device (LVAD) has dramatically improved the prognosis of patients with advanced heart failure.1 With ongoing technological innovation, patient survival and quality of life are further improving,2,3 and major complications related to LVAD such as pump thrombosis and stroke have decreased3; however, these complications have not been completely overcome. Infection remains a major complication in up to 60% of VAD patients and worsens prognosis and quality of life.
Source: Journal of Cardiac Failure - August 23, 2019 Category: Cardiology Authors: Yuki Kimura, Osamu Seguchi, Hiroki Mochizuki, Keiichiro Iwasaki, Koichi Toda, Yuto Kumai, Kensuke Kuroda, Seiko Nakajima, Emi Tateishi, Takuya Watanabe, Yorihiko Matsumoto, Satsuki Fukushima, Keisuke Kiso, Masanobu Yanase, Tomoyuki Fujita, Junjiro Kobayas Source Type: research

Bridging the Gap to LVAD Recovery and Explantation
Left ventricular assist device (LVAD) implantation continues to occur at an exceedingly high rate due to the donor and supply mismatch when it comes to heart transplantation. LVADs however do not come without risk and have high rates of significant bleeding, stroke, pump thrombosis and infection. Most of the clinical and research efforts thus far have been focused on LVAD insertion with the goal of destination therapy or as a bridge to transplant. The goal of bridge to recovery has often been underestimated despite multiple studies showing reverse remodeling of the myocardium.
Source: Journal of Cardiac Failure - July 31, 2019 Category: Cardiology Authors: Karlee K. Hoffman, Manreet Kanwar Tags: 361 Source Type: research

Mechanical Circulatory Support Driveline Infection Reduction through Nursing Quality Improvement
Infection in patients with left ventricular assist device is a leading cause of morbidity and mortality resulting in increased risk for additional complications such as bleeding, thrombosis and stroke. The purpose of this quality improvement project was to reduce driveline infections through implementation of an evidence-based bundled dressing kit and education to nursing staff.
Source: Journal of Cardiac Failure - July 31, 2019 Category: Cardiology Authors: Tania V. Randell, Tim Madeira, Noelle V. Pavlovic, Martha Abshire Tags: 335 Source Type: research

The Hemodynamic Profile of GI Bleeding in Continuous-Flow LVADs: Is it All About the Right Ventricle?
The last decade has seen LVADs emerge as an effective and durable means to support select patients with advanced heart failure. Despite improvements in heart failure morbidity and mortality with mechanical support, device-related complications remain a challenge. While rates of pump thrombosis, driveline infection and stroke have declined with improvements in pump design and patient care strategies, the risk of gastrointestinal (GI) bleeding has remained constant.1 GI bleeding remains the leading cause of hospital readmission following device implant, occurring in 30% of patients with continuous-flow LVADs and negatively i...
Source: Journal of Cardiac Failure - August 2, 2018 Category: Cardiology Authors: Christopher T. Sparrow, Joel D. Schilling Source Type: research

Diffuse Connective Tissue Diseases and Left-Ventricular Assist Devices: Insights from the National Inpatient Sample
Durable left-ventricular assist devices (LVAD) have become an increasingly frequent treatment strategy for end-stage heart failure (HF) but their use remains limited by complications including bleeding, thrombosis, and stroke. The impact of LVAD therapy on outcomes in HF patients with postulated higher risk comorbid conditions, such as diffuse connective tissue diseases (DCTD), has not been well studied to date. Given that these patients have an inherently higher risk of hematological complications than the general population, we aimed to investigate demographic characteristics and outcomes after LVAD implantation in this ...
Source: Journal of Cardiac Failure - August 1, 2018 Category: Cardiology Authors: Ann Gage, Vanessa Blumer, Miguel Ortiz, Emer Joyce Tags: 323 Source Type: research

Clinical Journey of Severe Heart Failure Patients after Left Ventricular Assistance Device Implant
This study aims to model the post-operative care pathway of patients after LVAD implementation using INTERMACS data.
Source: Journal of Cardiac Failure - August 1, 2017 Category: Cardiology Authors: Faezeh Movahedi, Lisa Lohmueller, Yiye Zhang, Rema Padman, James Antaki Source Type: research

Pages: 1  2